Products
Traxivitug Biosimilar Monoclonal Antibody (BK Polyomavirus VP1) for Research
Cat No.: GMP-Bios-INN-1426
Anti-BK Polyomavirus Major Capsid Protein VP1 therapeutic antibody (Pre-made Traxivitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Traxivitug (development code MAU-868) is a monoclonal antibody targeting BK polyomavirus major capsid protein VP1. It is developed by Novartis Pharmaceuticals and Amplyx Pharmaceuticals for Human polyomavirus infections in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1426-1mg | 1mg | 3090 |
| GMP-Bios-INN-1426-10mg | 10mg | |
| GMP-Bios-INN-1426-100mg | 100mg | |
| GMP-Bios-INN-1426-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Traxivitug biosimilar, Whole mAb: Anti-BK Polyomavirus Major Capsid Protein VP1 therapeutic antibody |
| INN Name | Traxivitug |
| Target | BK Polyomavirus Major Capsid Protein VP1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 8u5l:FF:HH:JJ:KK:NN |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Novartis Pharmaceuticals;Amplyx Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Human polyomavirus infections |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
